MRK

Top-Weighted Visa Leaps to Mid-$160s, More Earnings Reports

by

Top-Weighted Visa Leaps to Mid-$160s, More Reports Image: Visa (V) has been the top-weighted idea in the Best Ideas Newsletter for as long as we can remember. In December 2017, when we migrated to weighting ranges for ideas in the newsletter portfolio, the company’s “weight” was 8.6%. The image above shows its performance relative to the S&P 500 (SPY) since then. Source (pdf). — In alphabetical order by ticker symbol: GOOG, LLY, GE, GM, IR, LL, MA, MCD, MRK, PFE, TXRH, WDC — Alphabet (GOOG, GOOGL): Shares of Alphabet, the parent of Google, reported first-quarter performance April 29 that may have revealed weakness in the revenue story at the search giant. The miss was rather large on the top line during the quarter, but … Read more

Dividend Increases/Decreases for the Week of November 22

by

Below we provide a list of firms that raised their dividends during the week ending November 22. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week                          2020 Bulkers Ltd. (TTBKF): now $0.15 per share monthly dividend, was $0.01. AECOM (ACM): now $0.26 per share quarterly dividend, was $0.22. Agilent Technologies (A): now $0.248 per share quarterly dividend, was $0.236. Assurant (AIZ): now $0.80 per share quarterly dividend, was $0.72. Atea ASA (ATEAY): now $0.1591 per share semi-annual dividend, was $0.1401. Banca Mediolanum S.p.A. (BNCDY): now $0.7858 per share semi-annual dividend, … Read more

Nelson: The 16 Most Important Steps To Understand The Stock Market

by

A previous version of this article appeared on our website July 21, 2013. Refreshed and updated throughout, as of July 2018. By Brian Nelson, CFA After earning my MBA at the University of Chicago Booth School of Business and training stock and credit analysts from large organizations over the past decade or so, I have heard just about every question (though I admit I am still surprised by many things and remain a very humble student of the markets). I’ve also spent years perfecting the discounted cash flow process for large research organizations such as Morningstar and studied under one of the most famed aggressive growth investors of all time, Richard Driehaus. My knowledge runs the gamut from value through … Read more

Update: COVID-19 Vaccine Race

by

Image Source: Johnson & Johnson – Second Quarter of Fiscal 2020 IR Earnings Presentation By Callum Turcan The ongoing coronavirus (‘COVID-19’) pandemic has devasted the global economy (though things are starting to improve) and has fundamentally altered daily human life. According to a draft report from the World Health Organization (‘WHO’), there were 29 COVID-19 vaccine candidates undergoing clinical trials as of August 13 along with 138 other candidates undergoing preclinical evaluation. It is a race against the clock. Unfortunately, as of this writing on August 18, there have been ~170,000 COVID-19-related deaths in the US alone according to data from the US Centers for Disease Control and Prevention (‘CDC’). We are optimistic that one of the many “shots on … Read more

Nelson on Bogle, Part I

by

“The kind of commentary that makes broad generalizations about expectations of future returns is exactly why people are so eager to get into passive investment strategies. Since the 1920s, it seems as though the individual investor has assumed the stock market was rigged or impossible for average Joes to figure out, but instead of the “I’ll get it next time” mentality that was present leading to the crash of ’29, individual investors have “evolved” to the point that now the idea is if you can’t beat the market, just buy the whole thing. Leaders like Bogle continue to take tremendous shortcuts in explaining forecasts, leaving the average investor like a student trying to copy math homework off a peer that … Read more

Have Bristol-Myers Squibb’s Shares Finally Found Support?

by

Image Source: kennijima By Alexander J. Poulos and Brian Nelson, CFA The pharmaceutical industry remains an area of innovation with numerous life-altering therapies brought forth to treat the many afflictions that plague us. The industry lifeblood remains the tenuous path of research and study. There is not a foolproof way to predict how a compound will respond until full clinical trials are completed and analyzed, and even successful commercialization cannot be guaranteed should a drug be approved, regardless of the time and costs invested. A later stage clinical failure, for example, could devastate a smaller company, with its equity never to recover. That’s in part why we tend to prefer larger, more diversified, entities within the pharma/biotech arena as the … Read more

The “Hierarchy” of Valuentum Idea Generation

by

Let’s talk about this hierarchy of idea generation in this note. —  A version of this article was sent to members previously. New content has been added.  — Note: We continue to work to optimize the signal-to-noise ratio in our work, and we are evaluating expanding our update cycle to half-year periods to better bolster the signaling aspects of the Valuentum Buying Index (VBI). In our widely-read case study (see here), the VBI showed its ability to rank equity returns over a forward 12-month period, and we think a migration to less-frequent updating may make the most sense to better capture the forward-looking dynamics of the system. We think this will help weed out false breakouts and other noise that could be harmful. You shouldn’t think of … Read more

Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities

by

Key Takeaways: ·       The generic pharmaceutical industry will benefit from a patent expiry “mountain” in 2015. ·       Penetration and utilization rates of generics vary considerably by country. Japan, Italy, Spain, France, and Australia are most likely to see the greatest increases in generic penetration rates. ·       We expect further M&A activity in Japan, as global players seek to gain a generics stronghold in this under-penetrated, yet burgeoning pharmaceutical market. ·       Emerging market growth will offer significant opportunities for firms levered to Latin America and South Africa. ·       The potential for biosimilars remains a key catalyst for the group. ·       Ideas o       Teva Pharma (TEVA) is our favorite idea in the generics space thanks primarily to its upside valuation potential and global position. We’re particularly big fans … Read more